Cargando…

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

BACKGROUND: Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF (V600)-mutated melanoma treated in the Phase III coBRIM study. METHODS: In the coBRIM study, 49...

Descripción completa

Detalles Bibliográficos
Autores principales:	de la Cruz-Merino, Luis, Di Guardo, Lorenza, Grob, Jean-Jacques, Venosa, Alfredo, Larkin, James, McArthur, Grant A., Ribas, Antoni, Ascierto, Paolo A., Evans, Jeffrey T. R., Gomez-Escobar, Antonio, Barteselli, Giulio, Eng, Susan, Hsu, Jessie J., Uyei, Anne, Dréno, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483259/ https://www.ncbi.nlm.nih.gov/pubmed/28646893 http://dx.doi.org/10.1186/s12967-017-1246-0

Ejemplares similares

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM
por: Lewis, Karl D., et al.
Publicado: (2019)

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
por: Ascierto, Paolo A., et al.
Publicado: (2021)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
por: Ascierto, Paolo A, et al.
Publicado: (2015)

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma
por: Yan, Yibing, et al.
Publicado: (2014)

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
por: Ascierto, Paolo A., et al.
Publicado: (2020)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
por: Puzanov, Igor, et al.
Publicado: (2014)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies
por: Barteselli, Giulio, et al.
Publicado: (2022)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
por: Chapman, P B, et al.
Publicado: (2017)

Physicists brim with confidence
Publicado: (2000)

The best of SBP-BRiMS
por: Carley, Kathleen M.
Publicado: (2020)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021)

On the Treatment of Labour Delayed by Obstruction at the Pelvic Brim
por: Sloan, Samuel
Publicado: (1886)

On the Treatment of Labour Delayed by Obstruction at the Pelvic Brim
por: Sloan, Samuel
Publicado: (1886)

The Causation of the Movements of the Head at the Brim of the Rickety Pelvis
por: Hart, D. Berry
Publicado: (1882)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

On the Causation of the Movements of the Head at the Brim of the Rickety Pelvis (with Woodcuts)
por: Hart, D. Berry
Publicado: (1882)

Ectopic Kidney on the Pelvic Brim with Rare Anomalies in the Vascular Arrangement
por: Basu, Sunil Krishna
Publicado: (1953)

Demonstration of a New Method of Measuring the Pelvic Brim by Radiography
por: M'Kendrick, Archibald, et al.
Publicado: (1912)

Progressive nodular histiocytosis with dramatic response to cobimetinib
por: Berce, Philip C., et al.
Publicado: (2022)

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
por: Ascierto, Paolo A., et al.
Publicado: (2023)

On the Comparative Value of the Long Forceps and Turning in Cases of Contracted Pelvic Brim: With Cases
por: Milne, Alexander
Publicado: (1867)

Unilateral Ureteric Endometriosis at the Pelvic Brim Resulting in Complete Loss of Renal Function
por: Tanaka, Keisuke, et al.
Publicado: (2019)

Choroidal involvement in Rosai-Dorfman disease successfully treated with cobimetinib
por: Giuffrè, Chiara, et al.
Publicado: (2020)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
por: Lieu, Christopher H., et al.
Publicado: (2017)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
por: Unsworth, Amanda J., et al.
Publicado: (2018)

Successful side-viewing endoscopic hemoclipping for Dieulafoy-like lesion at the brim of a periampullary diverticulum
por: Lee, Wan Sik, et al.
Publicado: (2010)

On the Set of the Pelvis in the Body (Variations in the Inclination of the Brim Apart from Posture), and Its Obstetrical Significance
por: Barbour, A. H. Freeland
Publicado: (1900)

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Kawaguchi, Kei, et al.
Publicado: (2016)

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature
por: van Berge Henegouwen, J. M., et al.
Publicado: (2022)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells
por: Singh, Anjali, et al.
Publicado: (2015)

Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
por: Iafolla, Marco AJ, et al.
Publicado: (2019)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Safe Childbirth—The Three Essentials—1. Round Brim. 2. Flexible Joints. 3. Natural Posture
Publicado: (1937)

Cannot write session to /tmp/vufind_sessions/sess_r3p2jjqs1c7tiot6vcqmjmod23